The autoimmune diagnostic company expects its new assay to be available by the end of this year or in early 2027.

Is it hard to fly a helicopter in the Antarctic cold? What do penguins sound like? How about the instruments designed to test ...

Exagen ( (XGN)) has provided an announcement. On January 11, 2026, Exagen Inc. reported select preliminary unaudited results for the fourth quarter and full year ended December 31, 2025, indicating ...

Delhi Lab Gets Certification For Advanced TB Drug Testing. New Delhi, Jan 12 (IANS) Delhi's Intermediate Reference Laboratory ...

The approval significantly strengthens Delhi’s ability to diagnose multidrug-resistant (MDR-TB) and drug-resistant tuberculosis (XDR-TB). | Latest News Delhi ...

Delhi’s Intermediate Reference Laboratory (IRL) at the New Delhi Tuberculosis Centre has achieved its first certification from the Central Tuberculosis Division (CTD), Government of India, to conduct ...

Delhi IRL gets central certification to test key drugs for drug-resistant TB 13 Jan 2026 \| 12:03 AM. Pankaj Jain New Delhi, Jan 12 (UNI) Delhi’s Intermediate Reference Laborator ...

Record full year 2025 revenue, an increase of at least 19% over 2024 AVISE CTD trailing 12-month (TTM) ASP expansion by at least $30 compared to 2024 AVISE CTD test volume growth of at least 13,000, ...

The MarketWatch News Department was not involved in the creation of this content. CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune ...

CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth ...